NCT03960840 2026-04-17
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis
Phase 1/2 Active not recruiting
Clinical Trials
13 trialsNCT03934372 2026-04-16
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
Phase 1/2 Recruiting
NCT04521231 2026-04-16
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Phase 1/2 Recruiting
NCT04811560 2026-04-14
cAMeLot-1
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT07295951 2026-04-13
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT05473910 2026-04-08
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
TScan Therapeutics, Inc.
Phase 1 Recruiting
NCT05776134 2026-04-08
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Gilead Sciences
Available
NCT07109219 2026-04-06
ALLight
AstraZeneca
Phase 1/2 Recruiting
NCT04094311 2026-04-02
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
NCT03156790 2026-03-30
PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia
medac GmbH
Phase 2 Terminated
NCT04988555 2026-03-24
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc.
Phase 1/2 Recruiting
NCT03844048 2026-03-20
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie
Phase 3 Active not recruiting
NCT05748171 2026-03-20
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Pfizer
Phase 2 Recruiting